Business Context and Reporting Period
This Form 8-K is a current report filed by Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) on January 17, 2025. The filing discloses the entry into a material definitive agreement and the completion of an unregistered sale of equity securities. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transactions
- Debt Financing: Entered into a convertible promissory note with YA II PN, LTD ("Yorkville") for an original principal amount of $1,100,000.
- Interest Rate: Accrues at 8% annually, increasing to 18% upon an event of default.
- Maturity Date: December 31, 2025.
- Equity Financing: Completed closing of Series A Preferred Stock issuances to accredited investors on January 23, 2025, raising approximately $10 million at a purchase price of $1,000 per share.
- Subsidiary Equity: Series A Investors received a 13.91% non-voting equity ownership interest in two subsidiaries: SNAP Biosciences Inc. and GEAR Therapeutics Inc.
Material Changes and Terms
Convertible Note Terms
- Conversion Price: The lower of (i) a Fixed Price of $20.00 or (ii) a Variable Price equal to 95% of the lowest daily VWAP during the 5 consecutive trading days prior to conversion, subject to a $1.00 Floor Price.
- Amortization Event: Triggered if the daily VWAP is below the Floor Price for 5 of 7 consecutive trading days, or if issuance exceeds 99% of the Exchange Cap. This triggers monthly principal payments of $250,000 plus a 5% premium.
- Redemption: The Company may redeem the note early if the VWAP is less than the Fixed Price, subject to a 5% prepayment premium and 10 trading days' notice.
Equity Sale Details
- The Series A Preferred Stock terms were previously disclosed in an 8-K filed on June 20, 2024.
- Board member Christopher Calise, including through CJC Investment Trust, participated in the offering.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the anticipated benefits of the transactions, expected use of proceeds, and future financial performance. These statements are subject to risks and uncertainties that could cause actual results to vary materially.
Key Risks and Contingencies:
- Dilution Risk: The convertible note includes a variable conversion price that could result in significant dilution if the stock price declines, subject to the $1.00 floor.
- Liquidity Obligations: An "Amortization Event" could force the Company to make mandatory monthly principal payments, impacting cash flow.
- Regulatory Compliance: The report explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful without registration.
Investor Verification Checklist
- Verify the current daily VWAP of COEP stock to assess the likelihood of an "Amortization Event" triggering mandatory payments.
- Review the full text of the Convertible Promissory Note (Exhibit 10.1) for specific definitions of "Event of Default" and "Exchange Cap."
- Confirm the total outstanding debt and cash position post-transaction to evaluate liquidity runway.
- Check for any subsequent filings regarding the use of the $10 million raised from the Series A Preferred Stock.
- Monitor the stock price relative to the $20.00 Fixed Price and $1.00 Floor Price to understand potential conversion scenarios.